Latest Imatinib Stories
New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia.
CHICAGO, April 21 /PRNewswire/ -- A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.
Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells.
EAST HANOVER, N.J., Feb.
CAMBRIDGE, Mass., Feb.
A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract.
Team cautions that results are very preliminary and they cannot yet rule out other reasons for success.
FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...
EAST HANOVER, N.J., Dec.